goto bataviabiosciences.comBatavia Biosciences - CDMO For Viral Vectors & Viral Vaccines
Batavia Biosciences is a CDMO for Viral Vectors and Viral Vaccines from process develoment to clinical and commercial manufacturing.
Language: English
Beacon Diagnostics® Laboratory beacondiagnostics.com
Georgia Department of Economic Development | #1 State for Business georgia.org
Companies in Georgia don't just grow, they change the landscape. Companies in Georgia don't just grow, they change the landscape. Lifestyle and standard of living are two reasons Georgia continues to attract Fortune 500 companies and the skilled, educated workforce those businesses and others need to succeed.
coronadobiosciences.com coronadobiosciences.com
CEOCFO ceocfointerviews.com
PharmaTimes | in-depth news, features and insights for the pharmaceutical and healthcare sectors pharmatimes.com
Biotechnology Innovation Organization | BIO bio.org
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.
Softpedia - Free Downloads Encyclopedia softpedia.com
A library of over 1, 000, 000 free and free-to-try applications for Windows, Mac, Linux and Smartphones, Games and Drivers plus tech-focused news and reviews
BioPharm International biopharminternational.com
BioPharm International is the independent source for technical solutions and business insight for biopharmaceutical research, development, and manufacturing.
BioWorld: The Daily Biopharmaceutical and Medical Technology News Source bioworld.com
Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
Puma Biotechnology pumabiotechnology.com
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the acquisition, development and commercialization of novel therapeutics for the treatment of cancer. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer